Experimental PARP inhibitor combo trial halted early after just 3 patients
NCT ID NCT06509906
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a new drug called M9466 combined with standard chemotherapy in people with advanced solid tumors or colorectal cancer who had no other treatment options. Only 3 people took part before the study was stopped. The main goal was to check safety and find the right dose, but no conclusions can be drawn from such a small, terminated study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
M9466 (PARP1 inhibitor) combined with irinotecan, folinic acid, fluorouracil, and bevacizumab
What this could lead to
If successful, this could point toward a new combination treatment option for advanced solid tumors and colorectal cancer.
What could go wrong
This was a very early Phase 1 trial with only 3 participants and has been terminated, so results are extremely limited. The combination may cause significant side effects and may not work in larger groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Research SA
Elizabeth Vale, Australia
-
Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center
Pennington, New Jersey, 08534, United States
-
NEXT Barcelona - NEXT Barcelona
Barcelona, Spain
-
NEXT Madrid - Hospital Universitario Quironsalud Madrid
Pozuelo de Alarcón, Spain
-
National Cancer Center Hospital
Chūōku, Japan
-
Peter MacCallum Cancer Centre - Use the one with Account 2 VCCC
Parkville, Australia
-
Samsung Medical Center
Seoul, South Korea
-
Sarah Cannon Research Institute at Health One
Denver, Colorado, 80218, United States
-
Seoul National University Hospital
Seoul, South Korea
-
St George Private Hospital
Kogarah, Australia
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030-4009, United States
-
Vanderbilt University - 150912667
Nashville, Tennessee, 37232, United States